首页> 外文OA文献 >TRIF Regulates BIC/miR-155 via the ERK Signaling Pathway to Control the ox-LDL-Induced Macrophage Inflammatory Response
【2h】

TRIF Regulates BIC/miR-155 via the ERK Signaling Pathway to Control the ox-LDL-Induced Macrophage Inflammatory Response

机译:TRIF通过ERK信号通路调节BIC / miR-155以控制OX-LDL诱导的巨噬细胞炎症反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Toll/IL-1R-domain-containing adaptor-inducing IFN-β (TRIF) is an important adaptor for TLR3- and TLR4-mediated inflammatory signaling pathways. Recent studies have shown that TRIF plays a key role in vessel inflammation and atherosclerosis; however, the precise mechanisms are unclear. We investigated the mechanisms of the TRIF-regulated inflammatory response in RAW264.7 macrophages under oxidized low-density lipoprotein (ox-LDL) stimulation. Our data show that ox-LDL induces TRIF, miR-155, and BIC expression, activates the ERK1/2 and SOCS1-STAT3-NF-κB signaling pathways, and elevates the levels of IL-6 and TNF-α in RAW264.7 cells. Knockdown of TRIF using TRIF siRNA suppressed BIC, miR-155, IL-6, and TNF-α expression and inhibited the ERK1/2 and SOCS1-STAT3-NF-κB signaling pathways. Inhibition of ERK1/2 signaling also suppressed BIC and miR-155 expression. These findings suggest that TRIF plays an important role in regulating the ox-LDL-induced macrophage inflammatory response and that TRIF modulates the expression of BIC/miR-155 and the downstream SOCS1-STAT3-NF-κB signaling pathway via ERK1/2. Therefore, TRIF might be a novel therapeutic target for atherosclerosis.
机译:含有含有TLR3-和TLR4介导的炎症信号传导途径的Toll / IL-1R-域的适配器诱导IFN-β(TRIF)是一种重要的适配器。最近的研究表明,TRIF在血管炎症和动脉粥样硬化中起关键作用;然而,精确的机制尚不清楚。我们研究了氧化低密度脂蛋白(OX-LDL)刺激下RAW264.7巨噬细胞TRIF调节炎症反应的机制。我们的数据显示,Ox-LDL诱导TRIF,MIR-155和BIC表达,激活ERK1 / 2和SOCS1-STAT3-NF-κB信号传导途径,并提高RAW264.7中IL-6和TNF-α的水平细胞。使用TRIF siRNA抑制BIF,miR-155,IL-6和TNF-α表达的TRIF敲低,并抑制ERK1 / 2和SOCS1-STAT3-NF-κB信号传导途径。 ERK1 / 2信号传导的抑制也抑制了BIC和miR-155表达。这些发现表明,TRIF在调节OX-LDL诱导的巨噬细胞炎症反应方面发挥着重要作用,并且TRIF通过ERK1 / 2调节BIF / miR-155和下游SOCS1-Stat3-NF-κB信号传导途径的表达。因此,TRIF可能是动脉粥样硬化的新疗法靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号